Elanco Animal Health ( (ELAN) ) has released its Q2 earnings. Here is a breakdown of the information Elanco Animal Health presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elanco Animal Health Incorporated is a global leader in the animal health industry, providing innovative products and services to prevent and treat diseases in farm animals and pets, with a focus on creating value for farmers, pet owners, and veterinarians.
In its second quarter of 2025 earnings report, Elanco Animal Health reported a revenue increase of 5% year-over-year, reaching $1,241 million, with an adjusted net income of $131 million. The company has raised its full-year guidance, reflecting strong performance and favorable foreign exchange impacts.
Key financial highlights include an 8% organic constant currency revenue growth, driven by strong performance in U.S. Pet Health and innovative products like Credelio Quattro and Zenrelia. The company also reported an adjusted EBITDA of $238 million and improved its net leverage ratio to 4.0x adjusted EBITDA. Elanco is focusing on debt reduction, with plans to pay down $500 to $550 million in gross debt by the end of 2025.
Strategically, Elanco is expanding its innovation portfolio with new product launches and approvals, such as Zenrelia in the EU and TruCan Ultra CIV in the U.S. The company is also investing in productivity initiatives like Elanco Ascend, aiming to drive value in the coming years.
Looking ahead, Elanco’s management remains optimistic about sustained growth and innovation, with a focus on executing its strategic plans to enhance shareholder value and transform animal care in a dynamic market environment.